Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 1/20 | 0.71 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.59 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | FAAH | O00519 | 1/20 | 0.56 |
| ▸ | DPP4 | P27487 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2375476 | 1.00 | OPRK1 (0.71) | OPRK1POLBHDAC8OPRD1MEN1 | |
| SCHEMBL5366189 | 0.89 | HDAC8 (0.59) | OPRK1POLBHDAC8OPRD1DPP4 | |
| SCHEMBL7364618 | 0.88 | OPRK1 (0.57) | OPRK1POLBHDAC8OPRD1DPP4 | |
| SCHEMBL6966026 | 0.88 | OPRK1 (0.63) | OPRK1POLBMEN1KMT2AFAAH | |
| SCHEMBL7361667 | 0.86 | OPRK1 (0.57) | OPRK1POLBHDAC8OPRD1DPP4 | |
| SCHEMBL3133533 | 0.86 | OPRD1 (0.65) | OPRK1POLBHDAC8OPRD1DPP4 | |
| SCHEMBL6161830 | 0.86 | OPRD1 (0.65) | OPRK1POLBHDAC8OPRD1DPP4 | |
| SCHEMBL2375638 | 0.85 | OPRD1 (0.61) | OPRK1POLBHDAC8OPRD1DPP4 | |
| SCHEMBL2375634 | 0.85 | OPRD1 (0.61) | OPRK1POLBHDAC8OPRD1DPP4 | |
| SCHEMBL7360693 | 0.84 | HPGD (0.66) | OPRK1POLBHDAC8OPRD1DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110224210-A1 | NOVEL BIS-AMIDES AS ANTI-MALARIAL AGENTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224210-A1 | NOVEL BIS-AMIDES AS ANTI-MALARIAL AGENTS | CTSA, BECN1, HDAC6 | OPRK1 4074/4885POLB 1882/4885HDAC8 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.